Wuhan Hiteck Biological Pharma Co.,Ltd. (300683.SZ) has announced that the company recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration.
The notice, numbered 2026LP02967, confirms that the company's application for clinical trials of Epranemide for Injection, marketed under the brand name Shiaite, has been approved by the National Medical Products Administration.
The approval grants permission to conduct clinical trials of the product for the treatment of chondrosarcoma.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.